Pharmacokinetics and Pharmacogenomics of Ribociclib in Race-based Cohorts
Status:
Recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
The aim is to determine the pharmacological and biochemical association between ribociclib
exposure and CYP3A variants in African American/Blacks and Non-Hispanic White patients. The
investigators hypothesize that patients treated with ribociclib who are CYP3A5 poor
metabolizers may be exposed to higher levels of ribociclib than CYP3A5 intermediate or normal
metabolizers. The findings could allow clinicians to tailor treatments to maintain
therapeutic doses while limiting toxicities.
Phase:
Phase 4
Details
Lead Sponsor:
Georgetown University
Collaborators:
Breast Cancer Research Foundation Georgetown-Howard Universities Center for Clinical and Translational Science (GHUCCTS) Medstar Health Research Institute